As a follow up study to those that indicated that the synergistic effects of anti-CD40 and CpG increase classical activation [40], a combination of anti-CD40, CpG, and the chemotherapeutic agent cyclophosphamide was used to study treatment of melanoma in vivo. Here, CD40 is linked to melanoma.